Abstract

ARRY-520 is a novel kinesin spindle protein inhibitor that has demonstrated significant preclinical activity in solid tumor and hematologic cell line models. In clinical studies, while ARRY-520 has demonstrated significant single-agent activity in multiple myeloma, activity in solid tumors has been modest. To probe the disparity between preclinical and clinical activity in solid tumors, we have retrospectively evaluated the ability of preclinical models to inform clinical success by comparing ARRY-520 clinical activity in solid tumors, to preclinical activity in cell line xenograft and patient-derived explants.